HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)

Andrea Ciavattini, Luca Giannella, Rosa De Vincenzo, Jacopo Di Giuseppe, Maria Papiccio, Ankica Lukic, Giovanni Delli Carpini, Antonio Perino, Antonio Frega, Francesco Sopracordevole, Maggiorino Barbero, Murat Gultekin, Andrea Ciavattini, Luca Giannella, Rosa De Vincenzo, Jacopo Di Giuseppe, Maria Papiccio, Ankica Lukic, Giovanni Delli Carpini, Antonio Perino, Antonio Frega, Francesco Sopracordevole, Maggiorino Barbero, Murat Gultekin

Abstract

Human papillomavirus (HPV) related cervical cancer represents an issue of public health priority. The World Health Organization recommended the introduction of HPV vaccination in all national public programs. In Europe, vaccines against HPV have been available since 2006. In Italy, vaccination is recommended and has been freely offered to all young girls aged 11 years since 2008. Three prophylactic HPV vaccines are available against high- and low-risk genotypes. The quadrivalent vaccine contains protein antigens for HPV 6, 11, 16, and 18. The bivalent vaccine includes antigens for HPV 16 and 18. The nonavalent vaccine was introduced in 2014, and it targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Clinical trials demonstrated the effectiveness of the three vaccines in healthy young women. Likewise, all vaccines showed an excellent safety profile. The bivalent vaccine provides two doses in subjects aged between 9 and 14 years and three doses in subjects over 14 years of age. The quadrivalent vaccine provides two doses in individuals from 9 to 13 years and three doses in individuals aged 14 years and over. The nonavalent vaccine schedule provides two doses in individuals from 9 to 14 years of age and three doses in individuals aged 15 years and over at the time of the first administration. Preliminary results suggest that the HPV vaccine is effective in the prevention of cervical squamous intraepithelial lesions even after local treatment. Given these outcomes, in general, it is imperative to expand the vaccinated target population. Some interventions to improve the HPV vaccine's uptake include patient reminders, physicians-focused interventions, school-based vaccinations programs, and social marketing strategies. The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV) is committed to supporting vaccination programs for children and adolescents with a catch-up program for young adults. The SICPCV also helps clinical and information initiatives in developing countries to decrease the incidence of cervico-vaginal and vulvar pathology.

Keywords: HPV vaccine; cervical cancer; cervical intraepithelial neoplasia; human papillomavirus; primary prevention.

Conflict of interest statement

M.G. has received personal support from M.S.D. for travelling and speaking at medical symposiums. Other authors declare no conflict of interest.

References

    1. Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., Bray F. Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis. Lancet Glob. Health. 2020;8:e191–e203. doi: 10.1016/S2214-109X(19)30482-6.
    1. KO ai TUMORI da PAPILLOMAVIRUS. Paure, atteggiamenti e strategie di prevenzione. [(accessed on 5 March 2019)]; Available online: .
    1. Lin C., Franceschi S., Clifford G.M. Human Papillomavirus Types from Infection to Cancer in the Anus, According to Sex and HIV Status: A Systematic Review and Meta-Analysis. Lancet Infect. Dis. 2018;18:198–206. doi: 10.1016/S1473-3099(17)30653-9.
    1. Sias C., Salichos L., Lapa D., Del Nonno F., Baiocchini A., Capobianchi M.C., Garbuglia A.R. Alpha, Beta, Gamma Human PapillomaViruses (HPV) Detection with a Different Sets of Primers in Oropharyngeal Swabs, Anal and Cervical Samples. Virol. J. 2019;16:27. doi: 10.1186/s12985-019-1132-x.
    1. International Agency for Research on Cancer (IARC) A review of human carcinogens: Biological agents. Lyon. 2012;10:321.
    1. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int. J. Cancer. 2007;121:621–632. doi: 10.1002/ijc.22527.
    1. Mariani L., Monfulleda N., Alemany L., Vizza E., Marandino F., Vocaturo A., Benevolo M., Beatriz Quirós B., Lloveras B., Klaustermeier J.E., et al. Human Papillomavirus Prevalence and Type-Specific Relative Contribution in Invasive Cervical Cancer Specimens from Italy. BMC Cancer. 2010;10:259. doi: 10.1186/1471-2407-10-259.
    1. Preti M., Rotondo J.C., Holzinger D., Micheletti L., Gallio N., McKay-Chopin S., Carreira C., Privitera S.S., Watanabe R., Ridder R., et al. Role of Human Papillomavirus Infection in the Etiology of Vulvar Cancer in Italian Women. Infect. Agent. Cancer. 2020;15:20. doi: 10.1186/s13027-020-00286-8.
    1. Morbini P., Alberizzi P., Ferrario G., Capello G., De Silvestri A., Pedrazzoli P. The Evolving Landscape of Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma at a Single Institution in Northern Italy. Acta Otorhinolaryngol. Ital. 2019;39:9–17. doi: 10.14639/0392-100X-1905.
    1. Giorgi Rossi P., Chini F., Borgia P., Guasticchi G., Maria Carozzi F., Confortini M., Angeloni C., Buzzoni C., Buonaguro F.M. Epidemiologia del Papillomavirus umano (HPV), incidenza del cancro della cervice uterina e diffusione dello screening: Differenze fra macroaree in Italia. Epidemiol. Prev. 2012;36:108–119.
    1. Lupi S., Bergamini M., Guidi E., Gregorio P., HPV Collaborative Group Cross-sectional Seroprevalence of Antibodies Against 6, 11, 16 and 18 Human Papilloma Virus (HPV) Types Among Teenagers and Young Women in Italy. Ann. Dell’Istituto Super. Sanità. 2014;50:171–177. doi: 10.4415/ANN_14_02_11.
    1. Aspetti Epidemiologici Dell’infezione da Hpv. Istituto Superiore di Sanità (ISS). Aggiornamento del. [(accessed on 12 November 2015)]; Available online: .
    1. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017;35:5753–5755. doi: 10.1016/j.vaccine.2017.05.069.
    1. Gultekin M., Ramirez P.T., Broutet N., Hutubessy R. World Health Organization Call for Action to Eliminate Cervical Cancer Globally. Int. J. Gynecol. Cancer. 2020;30:426–427. doi: 10.1136/ijgc-2020-001285.
    1. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W.K., Ferris D.G., Steben M., Bryan J., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007;356:1928–1943. doi: 10.1056/NEJMoa061760.
    1. Ault K.A. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomized clinical trials. Lancet. 2007;369:1861–1868. doi: 10.1016/S0140-6736(07)60852-6.
    1. Kjaer S.K., Nygard M., Dillner J., Brooke Marshall J., Radley D., Li M., Munk C., Hansen B.T., Sigurdardottir L.G., Hortlund M., et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin. Infect. Dis. 2018;66:339–345. doi: 10.1093/cid/cix797.
    1. Luna J., Plata M., Gonzalez M., Correa A., Maldonado I., Nossa C., Radley D., Vuocolo S., Haupt R.M., Saah A. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS ONE. 2013;8:e83431. doi: 10.1371/journal.pone.0083431.
    1. Skinner S.R., Szarewski A., Romanowski B., Garland S.M., Lazcano-Ponce E., Salmerón J., Del Rosario-Raymundo M.R., Verheijen R.H.M., Quek S.C., da Silva D.P., et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213–2227. doi: 10.1016/S0140-6736(14)60920-X.
    1. Schwarz T.F., Galaj A., Spaczynski M., Wysocki J., Kaufmann A.M., Poncelet S., Suryakiran P.V., Folschweiller N., Thomas F., Lin L., et al. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15–55 years of age. Cancer Med. 2017;6:2723–2731. doi: 10.1002/cam4.1155.
    1. Joura E.A., AR Giuliano O.E., Iversen C., Bouchard C., Mao J., Mehlsen E.D., Moreira Jr E.D., Ngan Y., Kjeld Petersen L., Lazcano-Ponce E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 2015;372:711–723. doi: 10.1056/NEJMoa1405044.
    1. Huh W.K., Joura E.A., Giuliano A.R., Iversen O.E., de Andrade R.P., Ault K.A., Bartholomew D., Cestero R.M., Fedrizzi E.N., Hirschberg A.L., et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: A randomised, double-blind trial. Lancet. 2017;390:2143–2159. doi: 10.1016/S0140-6736(17)31821-4.
    1. Giuliano A.R., Joura E.A., Garland S.M., Huh W.K., Iversen O.E., Kjaer S.K., Ferenczy A., Kurman R.J., Ronnett B.M., Stoler M.H., et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo population. Gynecol. Oncol. 2019;154:110–117. doi: 10.1016/j.ygyno.2019.03.253.
    1. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., et al. HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364:1757–1765. doi: 10.1016/S0140-6736(04)17398-4.
    1. Ramet J., van Esso D., Meszner Z. European Academy of Paediatrics Scientific Working Group on Vaccination. Position paper-HPV and the primary prevention of cancer; Improving vaccine uptake by paediatricians. Eur. J. Pediatr. 2011;170:309–321. doi: 10.1007/s00431-010-1265-9.
    1. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170. doi: 10.1016/S0140-6736(07)60946-5.
    1. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., Spiessens B., Descamps D., Hardt K., Lehtinen M., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health. 2007;40:564–571. doi: 10.1016/j.jadohealth.2007.02.015.
    1. Arbyn M., Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev. Vaccines. 2018;17:1085–1091. doi: 10.1080/14760584.2018.1548282.
    1. Vesikari T., Brodszki N., van Damme P., Diez-Domingo J., Icardi G., Petersen L.K., Tran C., Thomas S., Luxembourg A., Baudin M. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr. Infect. Dis. J. 2015;34:992–998. doi: 10.1097/INF.0000000000000773.
    1. Mondiale de la S.O., World Health Organization Global Advisory Committee on Vaccine Safety. Wkly. Epidemiol. Rec. 2017;91:21–32.
    1. Gilmour S., Kanda M., Kusumi E., Tanimoto T., Kami M., Shibuya K. HPV vaccination programme in Japan. Lancet. 2013;382:768. doi: 10.1016/S0140-6736(13)61831-0.
    1. Brinth L., Theibel A.C., Pors K., Mehlsen J. Suspected side effects to the quadrivalent human papilloma vaccine. Dan. Med. J. 2015;62:A5064.
    1. Barboi A., Gibbons C.H., Axelrod F., Benarroch E.E., Biaggioni I., Chapleau M.W., Chelimsky G., Chelimsky T., Cheshire W.P., Claydon V.E., et al. Human papillomavirus (HPV) vaccine and autonomic disorders: A position statement from the American Autonomic Society. Auton. Neurosci. 2020;223:102550. doi: 10.1016/j.autneu.2019.05.002.
    1. Denny L. International Federation of Gynecology and Obstetrics. Safety of HPV vaccination: A FIGO statement. Int. J. Gynaecol. Obstet. 2013;123:187–188.
    1. Joura E.A., Kyrgiou M., Bosch F.X., Kesic V., Niemenen P., Redman C.W., Gultekin M. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur. J. Cancer. 2019;116:21–26. doi: 10.1016/j.ejca.2019.04.032.
    1. Evidence to Recommendation Table. Vaccination of Multiple Female Age Cohorts. [(accessed on 12 May 2017)]; Available online: .
    1. Evidence to Recommendation Table, Assessment of Gender-Based Immunization. [(accessed on 12 May 2017)]; Available online: .
    1. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira Jr E.D., Penny M.E., Aranda C., Vardas E., Moi J.H.H., Hillman R. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 2011;364:401–411. doi: 10.1056/NEJMoa0909537.
    1. Palefsky J., Giuliano A.R., Goldstone S., Moreira Jr E.D., Aranda C., Jessen H., Hillman R., Ferris D., Coutlee F., Stoler M.H., et al. HPV vaccine against Anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011;365:1576–1585. doi: 10.1056/NEJMoa1010971.
    1. Takla A., Wiese-Posselt M., Harder T., Meerpohl J.J., Röbl-Mathieu M., van der Sande T.M.M., Wichmann O., Zepp F., Klug S.J. Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsblatt Gesundh. Gesundh. 2018;61:1170–1186. doi: 10.1007/s00103-018-2791-2.
    1. Norwegian Ministry of Health and Care Services Free HPV Vaccine to Boys [Internet]. Oslo: Helse- Ogomsorgsdepartementet. [(accessed on 29 August 2018)]; Available online: .
    1. UK Department of Health & Social Care . Statement on HPV Vaccination—Joint Committee on Vaccination and Immunisation. Department of Health & Social Care; London, UK: 2018.
    1. Danish Ministry of Health Regeringen vil Tilbyde Gratis HPV-Vaccine til Drenge 2018 [Internet]. Copenhagen: Sundheds-og Ældreministeriet. [(accessed on 29 August 2018)]; Available online: .
    1. Ministero della Salute: Piano Nazionale Prevenzione Vaccinale 2017–2019. [(accessed on 17 January 2017)]; Available online: .
    1. Bruni L., Diaz M., Barrionuevo-Rosas L., Herrero R., Bray F., Bosch F.X., de Sanjosé S., Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob. Health. 2016;4:e453–e463. doi: 10.1016/S2214-109X(16)30099-7.
    1. Medeiros R., Vaz S., Rebelo T., Figueiredo-Dias M. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review. Acta. Med. Port. 2020;33:198–201. doi: 10.20344/amp.12259.
    1. Bergman H., Buckley B.S., Villanueva G., Petkovic J., Garritty C., Lutje V., Riveros-Balta A.X., Low N., Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst. Rev. 2019;11:CD013479. doi: 10.1002/14651858.CD013479.
    1. Arbyn M., Xu L., Simoens C., Martin-Hirsch P.P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst. Rev. 2018;5:CD009069. doi: 10.1002/14651858.CD009069.pub3.
    1. Walling E.B., Benzoni N., Dornfeld J., Bhandari R., Sisk B.A., Garbutt J., Colditz G. Interventions to improve HPV vaccine uptake: A systematic review. Pediatrics. 2016;138:e20153863. doi: 10.1542/peds.2015-3863.
    1. D’Addario M., Redmond S., Scott P., Egli-Gany D., Riveros-Balta A.X., Restrepo A.M., Low N. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis. Vaccine. 2017;35:2892–2901. doi: 10.1016/j.vaccine.2017.03.096.
    1. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., Sauvageau C., Scheifele D.W., Kollmann T.R., Halperin S.A., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309:1793–1802. doi: 10.1001/jama.2013.1625.
    1. Iversen O.E., Miranda M.J., Ulied A., Soerdal T., Lazarus E., Chokephaibulkit K., Block S.L., Skrivanek A., Nur Azurah A.G., Fong S.M., et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316:2411–2421. doi: 10.1001/jama.2016.17615.
    1. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., Ramjattan B., Hillemanns P., Catteau G., Dobbelaere K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study. Hum. Vaccines. 2011;7:1374–1386. doi: 10.4161/hv.7.12.18322.
    1. Leung T.F., Liu A.P., Lim F.S., Thollot F., Oh H.M., Lee B.W., Rombo L., Tan N.C., Rouzier R., Friel D., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Hum. Vaccines Immunother. 2015;11:1689–1702. doi: 10.1080/21645515.2015.1050570.
    1. Whitworth H.S., Gallagher K.E., Howard N., Mounier-Jack S., Mbwanji G., Kreimer A.R., Basu P., Kelly H., Drolet M., Brisson M., et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2020;38:1302–1314. doi: 10.1016/j.vaccine.2019.12.017.
    1. Pieri L., Tanini T., Bonanni P., Gambotto S., Biasi L., Siddu A. HPV vaccination. [(accessed on 27 January 2020)]; Available online: .
    1. Van Damme P., Bonanni P., Bosch F.X., Joura E., Kjaer S.K., Meijer C.J., Petry K.U., Soubeyrand B., Verstraeten T., Stanley M. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 2016;34:757e61. doi: 10.1016/j.vaccine.2015.12.063.
    1. Garland S.M., Cheung T.H., McNeill S., Petersen L.K., Romaguera J., Vazquez-Narvaez J., Bautista O., Shields C., Vuocolo S., Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33:6855–6864. doi: 10.1016/j.vaccine.2015.08.059.
    1. Velentzis L.S., Brotherton J.M.L., Canfell K. Recurrent disease after treatment for cervical pre-cancer: Determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric. 2019;22:596–602. doi: 10.1080/13697137.2019.1600500.
    1. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A., Huh W.K., Sings H.L., James M.K., Haupt R.M. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical anovulvar disease: Retrospective pooled analysis of trial data. BMJ. 2012;344:e1401. doi: 10.1136/bmj.e1401.
    1. Garland S.M., Paavonen J., Jaisamrarn U., Naud P., Salmeron J., Chow S.N., Apter D., Castellsagué X., Teixeira J.C., Skinneret S.R., et al. Prior human papillomavirus-16/18 AS04- adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int. J. Cancer. 2016;139:2812-e26. doi: 10.1002/ijc.30391.
    1. Kang W.D., Choi H.S., Kim S.M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol. Oncol. 2013;130:264-e8. doi: 10.1016/j.ygyno.2013.04.050.
    1. Ghelardi A., Parazzini F., Martella F., Pieralli A., Bay P., Tonetti A., Svelato A., Bertacca G., Lombardi S., Joura E.A. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol. Oncol. 2018;151:229–234. doi: 10.1016/j.ygyno.2018.08.033.
    1. Petrillo M., Dessole M., Tinacci E., Saderi L., Muresu N., Capobianco G., Cossu A., Dessole S., Sotgiu G., Piana A. Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution’s Experience. Vaccines. 2020;8:45. doi: 10.3390/vaccines8010045.
    1. Van Doorn L.J., Molijn A., Kleter B., Quint W., Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 2006;44:3292–3298. doi: 10.1128/JCM.00539-06.
    1. Hildesheim A., Gonzalez P., Kreimer A.R., Wacholder S., Schussler J., Rodriguez A.C., Porras C., Schiman M., Sidawy M., Schiller J.T., et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am. J. Obstet. Gynecol. 2016;215:212-e1. doi: 10.1016/j.ajog.2016.02.021.
    1. Sand F.L., Kjaer S.K., Frederiksen K., Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int. J. Cancer. 2019 doi: 10.1002/ijc.32752.
    1. Bartels H.C., Postle J., Rogers A.C., Brennan D. Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: A meta-analysis. Int. J. Gynecol. Cancer. 2020 doi: 10.1136/ijgc-2020-001197.
    1. Lichter K., Krause D., Xu J., Tsai S.H.L., Hage C., Weston E., Eke A., Levinson K. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet. Gynecol. 2020 doi: 10.1097/AOG.0000000000003833.
    1. Comment to the Vaccination Coverage as of 31/12/2017 for HPV. Italian Ministry of Health. [(accessed on 17 June 2019)]; Available online: .
    1. Piano Nazionale Prevenzione Vaccinale 2017–2019 (Pnpv) [(accessed on 17 January 2017)]; Available online: .
    1. Niccolai L.M., Hansen C.E. Practice and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review. JAMA Pediatr. 2015;169:686–692. doi: 10.1001/jamapediatrics.2015.0310.
    1. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. Technical Guidance. [(accessed on 30 March 2020)]; Available online: .
    1. Scheller N.M., Pasternak B., Mølgaard-Nielsen D., Svanström H., Hviid A. Quadrivalent HPV vaccination and risk of adverse pregnancy outcomes. N. Engl. J. Med. 2017;376:1223–1233. doi: 10.1056/NEJMoa1612296.
    1. Faber M.T., Duun-Henriksen A.K., Dehlendorff C., Tatla M.K., Munk C., Kjaer S.K. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy. Vaccine. 2019;37:265–271. doi: 10.1016/j.vaccine.2018.11.030.
    1. Martínez-Gómez X., Curran A., Campins M., Alemany L., Rodrigo-Pendás J.Á., Borruel N., Castellsagué X., Díaz-de-Heredia C., Moraga-Llop F.A., Del Pino M., et al. Multidisciplinary, Evidence-Based Consensus Guidelines for Human Papillomavirus (HPV) Vaccination in High-Risk Populations. Euro Surveill. 2019;24:1700857. doi: 10.2807/1560-7917.ES.2019.24.7.1700857.
    1. Perino A., Giovannelli L., Schillaci R., Ruvolo G., Fiorentino F.P., Alimondi P., Cefalù E., Ammatuna P. Human papillomavirus infection in couples undergoing in vitro fertilization procedures: Impact on reproductive outcomes. Fertil. Steril. 2011;95:1845–1848. doi: 10.1016/j.fertnstert.2010.11.047.
    1. Schillaci R., Capra G., Bellavia C., Ruvolo G., Scazzone C., Venezia R., Perino A. Detection of oncogenic human papillomavirus genotypes on spermatozoa from male partners of infertile couples. Fertil. Steril. 2013;100:1236–1240. doi: 10.1016/j.fertnstert.2013.06.042.
    1. Capra G., Schillaci R., Bosco L., Roccheri M.C., Perino A., Ragusa M.A. HPV infection in semen: Results from a new molecular approach. Epidemiol. Infect. 2019;147:e177. doi: 10.1017/S0950268819000621.
    1. Golob B., Poljak M., Verdenik I., Kolbezen Simoniti M., Vrtačnik Bokal E., Zorn B. High HPV infection prevalence in men from infertile couples and lack of relationship between seminal HPV infection and sperm quality. BioMed. Res. Int. 2014;2014:956901. doi: 10.1155/2014/956901.
    1. Garolla A., Engl B., Pizzol D., Ghezzi M., Bertoldo A., Bottacin A., Noventa M., Foresta C. Spontaneous fertility and in vitro fertilization outcome: New evidence of human papillomavirus sperm infection. Fertil. Steril. 2016;105:65–72. doi: 10.1016/j.fertnstert.2015.09.018.
    1. Lyu Z., Feng X., Li N., Zhao W., Wei L., Chen Y., Yang W., Ma H., Yao B., Zhang K., et al. Human papillomavirus in semen and the risk for male infertility: A systematic review and meta-analysis. BMC Infect. Dis. 2017;17:714. doi: 10.1186/s12879-017-2812-z.
    1. Garolla A., De Toni L., Bottacin A., Valente U., De Rocco Ponce M., Di Nisio A., Foresta C. Human Papillomavirus Prophylactic Vaccination improves reproductive outcome in infertile patients with HPV semen infection: A retrospective study. Sci. Rep. 2018;8:912. doi: 10.1038/s41598-018-19369-z.
    1. Tangal S., Taşçı Y., Pabuçcu E.G., Çağlar G.S., Haliloğlu A.H., Yararbaş K. DNA fragmentation index and human papilloma virus in males with previous assisted reproductive technology failures. Turk. J. Urol. 2018;45:12–16. doi: 10.5152/tud.2018.96393.
    1. Depuydt T., Beert J., Bosmans E., Salembier G. Human Papillomavirus (HPV) virion induced cancer and subfertility, two sides of the same coin. Facts Views Vis. Obgyn. 2016;8:211–222.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi